Clinical Trial of 'Gan Shen An' Granules treatment on deficiency of liver-yin and kidney-yin in Type 2 diabetes patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004179

Enrollment

Unknown

Registered

2014-01-21

Start date

2014-02-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

deficiency of liver-yin and kidney-yin

Interventions

trial group:GanShenAn Granules

Control group:GanShenAn Granules

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 40 to 75 years old, male or female; 2. Diagnosed with deficiency of liver-yin and kidney-yin and TCM; 3. At least one principal syndrome score up to 3 points; 4. Diagnosed with type 2 diabetes, glycosylated hemoglobin values = 6%, and = 8%; 5. understood the whole testing process wellvoluntarily participated and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Have suffered from diabetic ketoacidosis, ketoacidosis, severe infection and trauma, major surgery within the past one month; 2. Accompanied by pulmonary insufficiency, heart failure, acute myocardial infarction and other serious disease; 3. Patients with liver or kidney dysfunction; 4. With malignant hypertension: systolic blood pressure = 180 mm Hg (1 mm Hg = 0.133 kPa) or diastolic blood pressure = 100mm Hg; 5. Mergered proliferative diabetic retinopathy; diabetic nephropathy, staging of disease progression to stage V Mogensen persons; 6. With lumbar disc disease or discomfort; suffering from cervical spondylosis and vertigo; 7. With cerebrovascular disease, cognitive disorders; 8. Pregnancy, pregnant or lactating women prepare; 9. Have taken in 4 weeks or related neuropathy treatment drugs due to neuropathy; 10. allergy to this product; 11. Psychiatric patients; 12. Patients have participated in other clinical trials within the past three months.

Design outcomes

Primary

Measure	Time frame
Change of reduction scores of TCM main zhen 'deficiency of liver-yin and kidney-yin';	—

Secondary

Measure	Time frame
SF - 36 survival quality score;Change of reduction scores of TCM secondary zhen 'deficiency of liver-yin and kidney-yin';	—

Countries

China

Contacts

Public ContactMEI Linghua

Shanghai University of Chinese Medicine

Justin_mainland@sina.com+86 021-50272971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026